Viking Therapeutics Stock: A Watershed Moment in Obesity Treatment?

Today marks a pivotal juncture for Viking Therapeutics as the biotech firm prepares to unveil critical Phase 3 trial design details for its promising drug candidate, VK2735, at ObesityWeek 2025. The presentation, scheduled for 8:30 PM CET, could position the company as a significant contender in the multi-billion dollar obesity therapeutics sector.

Viking enters this crucial phase with a robust financial position, providing substantial resources for its advanced clinical programs. Recent disclosures reveal:

• Cash and liquidity totaling $715 million as of September 30, 2025
• Capital reserves deemed sufficient to fund the entire Phase 3 clinical program
• A significant increase in research and development investment, reaching $90.0 million in the third quarter of 2025

This financial commitment is reflected in the company's net loss, which widened to $90.8 million, underscoring the capital-intensive nature of late-stage clinical development.

The VANQUISH Program: Pathway to Approval

Central to today's announcements is the VANQUISH-1 trial, a registrational Phase 3 study designed to support regulatory approval for the subcutaneous formulation of VK2735. Dr. Karen Modesto, Vice President of Clinical Development, will present the study's design, marking a fundamental corporate milestone.

VK2735's Competitive Profile

The dual GLP-1/GIP receptor agonist has demonstrated compelling efficacy in earlier studies, suggesting potential to challenge established market leaders. Phase 2 data revealed:

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

• Weight reduction of up to 14.7% after a 13-week treatment period
• An oral formulation achieving up to 12.2% weight loss
• No observed plateau effect in weight reduction during the trial period

Viking's strategy of developing both subcutaneous and oral formulations may provide a distinct market advantage, offering dosing flexibility and potential efficacy benefits against dominant players like Novo Nordisk and Eli Lilly.

Accelerated Clinical Timelines

The company's development schedule appears to be gaining momentum, with management reporting rapid patient enrollment. Key milestones include:

• Completion of patient recruitment for VANQUISH-1 anticipated in the fourth quarter of 2025
• VANQUISH-2 trial initiation expected to follow in the first quarter of 2026
• A new maintenance dosing study broadening the clinical development strategy

This accelerated timeline indicates strong interest from both clinical investigators and patients—a positive indicator in this highly competitive market.

Near-Term Catalysts

Beyond today's presentations, Viking has several imminent value-driving events:

• Additional Phase 2a data scheduled for release tomorrow, November 6
• Presentations at the American Heart Association conference on November 8
• Planned regulatory discussions concerning the oral formulation in Q4 2025

With solid financial resources and accelerated clinical progress, Viking Therapeutics is positioning itself for potential significant value creation in 2026. The central question remains whether its clinical assets can effectively compete against the entrenched pharmaceutical giants in the obesity treatment landscape.